99 related articles for article (PubMed ID: 14579030)
41. Novel therapies for rheumatoid arthritis.
Tremoulet AH; Albani S
Expert Opin Investig Drugs; 2006 Nov; 15(11):1427-41. PubMed ID: 17040201
[TBL] [Abstract][Full Text] [Related]
42. [Attitude of patient associations to clinical trials of new drugs].
Tybkjaer HW; Witte L; Johannessen MB
Ugeskr Laeger; 2003 Apr; 165(16):1688-90. PubMed ID: 12756833
[TBL] [Abstract][Full Text] [Related]
43. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel therapeutics - exciting gifts but how best to use them?
McInnes IB; O'Dell JR
Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):441-2. PubMed ID: 20732642
[No Abstract] [Full Text] [Related]
44. Rilonacept--CAPS and beyond.
Stahl N; Radin A; Mellis S
Ann N Y Acad Sci; 2009 Dec; 1182():124-34. PubMed ID: 20074281
[TBL] [Abstract][Full Text] [Related]
45. IL-1 trap. Regeneron/Novartis.
Gabay C
Curr Opin Investig Drugs; 2003 May; 4(5):593-7. PubMed ID: 12833655
[TBL] [Abstract][Full Text] [Related]
46. Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis.
Antoniu SA
Expert Opin Investig Drugs; 2012 Nov; 21(11):1607-18. PubMed ID: 22839355
[TBL] [Abstract][Full Text] [Related]
47. Inflammation 2005 - Seventh World Congress. Highlights II.
Enefer S
IDrugs; 2005 Oct; 8(10):791-2. PubMed ID: 16254792
[No Abstract] [Full Text] [Related]
48. Inflammation 2005 - Seventh World Congress. Rheumatoid arthritis and cell signaling.
Parnham MJ
IDrugs; 2005 Oct; 8(10):786-8. PubMed ID: 16254790
[TBL] [Abstract][Full Text] [Related]
49. Experimental drug that injured UK volunteers resumes in human trials.
Dyer O
BMJ; 2015 Apr; 350():h1831. PubMed ID: 25838401
[No Abstract] [Full Text] [Related]
50. Blockade of interleukin-6 in murine sepsis revisited: is there an indication for a new therapy in human patients?
Kurdowska A; Krupa A
Crit Care Med; 2011 Jun; 39(6):1582-3. PubMed ID: 21610636
[No Abstract] [Full Text] [Related]
51. Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells.
Fogal B; Yi T; Wang C; Rao DA; Lebastchi A; Kulkarni S; Tellides G; Pober JS
J Immunol; 2011 Dec; 187(12):6268-80. PubMed ID: 22084439
[TBL] [Abstract][Full Text] [Related]
52. [Rheumatology].
Scherer HU; Burmester GR
Internist (Berl); 2005 Aug; 46(8):882-91. PubMed ID: 15997385
[TBL] [Abstract][Full Text] [Related]
53. [Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
Lakartidningen; 2001 Feb; 98(8):828-31. PubMed ID: 11265568
[TBL] [Abstract][Full Text] [Related]
54. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
Manger B;
Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
[No Abstract] [Full Text] [Related]
55. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Cohen SB
Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
[TBL] [Abstract][Full Text] [Related]
56. Emerging therapeutics for rheumatoid arthritis.
Bingham CO
Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
[TBL] [Abstract][Full Text] [Related]
57. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
Perniok A; Rubbert-Roth A
Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
[TBL] [Abstract][Full Text] [Related]
58. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
